| scholarly article | Q13442814 |
| P50 | author | Klemens Budde | Q72992120 |
| Hans-Hellmut Neumayer | Q112192736 | ||
| P2093 | author name string | Ingrid Mai | |
| Ivar Roots | |||
| Steffen Bauer | |||
| Elke Störmer | |||
| Hagen Krüger | |||
| Andreas Johne | |||
| P2860 | cites work | Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin | Q24675666 |
| St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor | Q24681068 | ||
| Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of [...] | Q28115162 | ||
| Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure | Q28366014 | ||
| St John's wort, a herbal antidepressant, activates the steroid X receptor. | Q31438381 | ||
| Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery | Q33904220 | ||
| Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. | Q33907273 | ||
| Interaction between cyclosporine and Hypericum perforatum (St. John's wort) after organ transplantation | Q34421963 | ||
| Biologically active and other chemical constituents of the herb of Hypericum perforatum L. | Q34443600 | ||
| Maintenance immunosuppression in the renal transplant recipient: an overview | Q34453652 | ||
| Hyperforin as a possible antidepressant component of hypericum extracts | Q34751517 | ||
| Cyclosporine toxicity to organs other than the kidney | Q37769956 | ||
| Cyclosporin metabolism in transplant patients | Q40840779 | ||
| Cyclosporin clinical pharmacokinetics | Q40918376 | ||
| Alternative cyclosporine metabolic pathways and toxicity | Q40966365 | ||
| Toxicity of cyclosporine metabolites | Q41715457 | ||
| Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation | Q42108944 | ||
| Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily | Q43422277 | ||
| Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort ( Hypericum perforatum ). | Q43859427 | ||
| Cyclosporine monitoring in liver allograft recipients: two distinct patterns of blood level derangement associated with nephrotoxicity | Q44005714 | ||
| Association of very high blood levels of cyclosporin metabolites with clinical complications after liver transplantation | Q44085904 | ||
| Biologic activity of cyclosporine metabolites | Q44403123 | ||
| Activity of cyclosporin metabolites M17 and M1. | Q45127641 | ||
| Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein | Q48224458 | ||
| Investigations on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile—isolation of 12 new cyclosporine metabolites | Q50701482 | ||
| Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. | Q52968365 | ||
| Indinavir concentrations and St John's wort. | Q55033637 | ||
| Effect of enzyme induction on Sandimmun (cyclosporin A) biotransformation and hepatotoxicity in cultured rat hepatocytes and in vivo | Q67270580 | ||
| Investigations on the metabolic pathways of cyclosporine: II. Elucidation of the metabolic pathways in vitro by human liver microsomes | Q67854382 | ||
| Additive and synergistic effects of cyclosporine metabolites on glomerular mesangial cells | Q67978133 | ||
| Liquid-chromatographic measurement of cyclosporin A and its metabolites in blood, bile, and urine | Q68124790 | ||
| The nephrotoxic effects of cyclosporine metabolites | Q68147444 | ||
| Pharmacokinetic interaction between cyclosporin and diltiazem | Q68787570 | ||
| Sandimmun metabolites: their potential to cause adverse reactions in the rat | Q68807245 | ||
| Differential effects of cyclosporin on hepatic and renal heme, cytochrome P-450 and drug metabolism. Possible role in nephrotoxicity of the drug | Q69186364 | ||
| Urinary excretion of ciclosporin and 17 of its metabolites in renal allograft recipients | Q69389412 | ||
| Biotransformation and distribution in blood of cyclosporine and its metabolites | Q69677371 | ||
| Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum) | Q73145709 | ||
| Interaction of Hypericum perforatum (St. John's wort) with cyclosporin A metabolism in a patient after liver transplantation | Q73246112 | ||
| St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 | Q73443725 | ||
| Acute heart transplant rejection due to Saint John's wort | Q73465831 | ||
| Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine | Q73794585 | ||
| Drug interaction of St John's wort with cyclosporin | Q73923310 | ||
| Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test | Q74626886 | ||
| Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients | Q74649806 | ||
| St John's wort: a hidden risk for transplant patients | Q77708483 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| cyclosporine | Q367700 | ||
| P304 | page(s) | 203-211 | |
| P577 | publication date | 2003-02-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients | |
| P478 | volume | 55 |
| Q39125213 | A Model for Predicting the Interindividual Variability of Drug-Drug Interactions |
| Q38074664 | A brief study of toxic effects of some medicinal herbs on kidney |
| Q50094359 | Adulteration and Counterfeiting of Online Nutraceutical Formulations in the United States: Time for Intervention? |
| Q38011191 | An update on the ability of St. John's wort to affect the metabolism of other drugs |
| Q35870072 | Case-based online modules to teach graduate-level nursing students about complementary and alternative medical therapies |
| Q86877097 | Chinese herbal medicines and chronic kidney disease: a positive outcome in a large patient study in Taiwan |
| Q38200541 | Ciclosporin 10 years on: indications and efficacy. |
| Q38748975 | Clinical determinants of calcineurin inhibitor disposition: a mechanistic review |
| Q47774682 | Clinical risks of St John's Wort (Hypericum perforatum) co-administration |
| Q38011807 | Combination therapy of Western drugs and herbal medicines: recent advances in understanding interactions involving metabolism and efflux. |
| Q34363569 | Complementary and alternative medicine: assessing the evidence for immunological benefits |
| Q21284735 | Cyclosporine and herbal supplement interactions |
| Q43767845 | Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential |
| Q37526981 | Dietary regulation of P-gp function and expression |
| Q36745170 | Dietary supplements in patients with cancer: risks and key concepts, part 2. |
| Q57179831 | Drug Interactions with St. John's Wort |
| Q35879020 | Drug interactions with St John's wort : mechanisms and clinical implications |
| Q83274402 | Drug interactions with herbal medicines |
| Q43183967 | Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers |
| Q43239052 | Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity |
| Q24651117 | Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide |
| Q37779320 | Effects of herbal products on the metabolism and transport of anticancer agents |
| Q38825266 | Evaluation of the effect of fluconazole on the pharmacokinetics of cyclosporin A in healthy dogs after a single dose and at steady-state |
| Q36016526 | Food-drug interactions via human cytochrome P450 3A (CYP3A). |
| Q24656624 | Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics |
| Q45041991 | General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information |
| Q28176037 | Herb-drug interactions: a literature review |
| Q36014951 | Herb-drug interactions: an overview of the clinical evidence |
| Q92074065 | Herbal Interaction With Chemotherapeutic Drugs-A Focus on Clinically Significant Findings |
| Q39030813 | Herbal Medicines: challenges in the modern world. Part 5. status and current directions of complementary and alternative herbal medicine worldwide. |
| Q34312035 | Herbal modulation of P-glycoprotein |
| Q44429983 | Identification and exploration of herb-drug combinations used by cancer patients |
| Q45062240 | Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers |
| Q35023736 | Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone |
| Q35615173 | Interaction of St John's wort with conventional drugs: systematic review of clinical trials |
| Q57269371 | Isochlorogenic acid A affects P450 and UGT enzymes in vitro and in vivo |
| Q52949277 | MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. |
| Q35927418 | Medicinal herbal extracts -- renal friend or foe? Part one: the toxicities of medicinal herbs. |
| Q36278312 | Natural health product interactions with medication |
| Q41619007 | Ophiopogon japonicus strains from different cultivation regions exhibit markedly different properties on cytotoxicity, pregnane X receptor activation and cytochrome P450 3A4 induction |
| Q38574619 | Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences |
| Q42775755 | Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance |
| Q33204911 | Pharmacokinetic interactions of drugs with St John's wort |
| Q35827719 | Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. |
| Q36551135 | Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents |
| Q33434762 | Simultaneous quantitative determination of cyclosporine A and its three main metabolites (AM1, AM4N and AM9) in human blood by liquid chromatography/mass spectrometry using a rapid sample processing method |
| Q36200170 | Sirolimus: the evidence for clinical pharmacokinetic monitoring. |
| Q48258575 | St John's wort greatly decreases the plasma concentrations of oral S-ketamine |
| Q43182631 | St John's wort greatly reduces the concentrations of oral oxycodone |
| Q46991286 | St. John's wort does not interfere with therapeutic drug monitoring of 12 commonly monitored drugs using immunoassays. |
| Q34657381 | Sucralose, a synthetic organochlorine sweetener: overview of biological issues |
| Q35827865 | The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials |
| Q35725196 | Therapeutic drug monitoring of cyclosporine and area under the curve prediction using a single time point strategy: appraisal using peak concentration data |
| Q35994591 | Update on liver transplantation using cyclosporine |
| Q35841358 | Use of antidepressant drugs in transplant recipients |
| Q42140204 | Which medications used in paediatric practice have demonstrated natural health product-drug interactions?: Part A: Evidence-based answer and summary |
Search more.